Company intelligence / Profile preview

Marvelway

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Lead compound MB‑204, a novel fluorinated derivative of Istradefylline, has shown efficacy in preclinical studies across multiple neurological and neurodevelopmental disorders. cGMP synthesis and toxicology studies are complete with preparations underway for Phase I clinical trials. Preclinical data show significant promise versus existing therapies such as Trofinetide in Rett Syndrome models.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculeSynthetic derivative compound
Industry: Biotech

Beyond the preview

Go deeper on Marvelway.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marvelway.

Explore the full profile